#United States #New York #Levi & Korsinsky #Rocket Pharmaceuticals #RCKT

Class Action Lawsuit Alert for Rocket Pharmaceuticals Investors

Levi & Korsinsky, LLP, a prominent law firm specializing in securities litigation, has brought to the attention of investors in Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) that a class action lawsuit is underway. The suit seeks justice for shareholders affected by alleged securities fraud which occurred between February 27, 2025, and May 26, 2025. This situation has become a focal point for those who invested in the company, as they are urged to act swiftly given the approaching deadline for a lead plaintiff by August 11, 2025.

Understanding the Class Action Suit

The class action aims to recover losses incurred by investors due to misleading statements made by Rocket Pharmaceuticals regarding its drug, RP-A501. The lawsuit claims that the company misrepresented the safety and efficacy of its product during clinical trials, while knowledge of serious adverse events, including participant fatalities, was concealed. This misrepresentation allegedly inflated the stock value, deceiving investors who purchased shares at artificially high prices.

On May 27, 2025, the FDA placed a clinical hold on the RP-A501 Phase 2 pivotal study after a serious adverse event, notably a participant death that occurred after a significant amendment to the clinical trial protocol was put in place without notifying investors. These revelations led to a significant stock price decline of around 37% in just one trading day.

Next Steps for Affected Investors

Investors who believe they have been affected by this situation should act quickly to have a chance at being recognized as lead plaintiffs in this case. While the cut-off date is approaching, interested individuals can reach out to the firm for more information and submission of necessary forms. Notably, participating in this class action could be done without any out-of-pocket expenses, amplifying its appeal to affected shareholders.

Why Choose Levi & Korsinsky?

Levi & Korsinsky has a robust history of advocating for shareholders, having secured hundreds of millions for investors through various high-stakes litigation cases over the past two decades. The firm boasts a team of over 70 dedicated employees experienced in handling complex securities disputes, consistently ranking among the top law firms in the United States for securities litigation. Their success speaks volumes about their capability and expertise in navigating the intricacies of class action lawsuits.

Contact Information

For Rocket Pharmaceuticals investors seeking further details or assistance regarding the lawsuit, they are encouraged to contact Joseph E. Levi, Esq. at Levi & Korsinsky. The firm’s offices are located at 33 Whitehall Street, 17th Floor, New York, NY 10004. Investors can reach out via email at [email protected] or call at (212) 363-7500 to ensure their interests are safeguarded amid the ongoing legal proceedings.

• ---

Investors should take these developments seriously as the repercussions from these allegations continue to unfold, highlighting the importance of transparency in the healthcare sector, and the financial stakes for shareholders involved in pharmaceutical advancements.